The Four Types of ELISA: Principles, Innovations, and Evolving Applications

1. In-Depth Analysis of the Four Classic ELISA Types

Through constant optimization, several ELISA formats have been developed to cater to different applications, primarily distinguished by their detection principles and procedural steps. The four fundamental types are direct, indirect, Sandwich, and competitive ELISA.

1.1 Direct ELISA

1.2 Indirect ELISA

1.3 Sandwich ELISA

1.4 Competitive ELISA

Table 1. Advantages and disadvantages of each ELISA type

Selection Decision Guide

Choosing the optimal ELISA format depends on several key factors: the nature of the analyte (size, availability, purity), the required assay performance (sensitivity, specificity), the available reagents (antibodies), and the experimental context (throughput, cost). The following logic flow provides a practical guide for selection:

Key Decision Notes:

Choosing the optimal ELISA format depends on several key factors: the nature of the analyte (size, availability, purity), the required assay performance (sensitivity, specificity), the available reagents (antibodies), and the experimental context (throughput, cost). The following logic flow provides a practical guide for selection:

• Sandwich ELISA is the first choice for quantifying specific proteins in complex samples due to its superior specificity and sensitivity. However, it requires a validated pair of antibodies recognizing non-overlapping epitopes, which can be a significant development hurdle ^[3].
• Indirect ELISA is the most versatile and commonly used format for detecting antibodies (e.g., in serology) or for antigen detection when only one specific antibody is available. Its signal amplification makes it more sensitive than the direct format ^[2].
• Direct ELISA is best suited for high-throughput screening of purified antigens when conjugated primary antibodies are already available, prioritizing speed over maximum sensitivity.
• Competitive ELISA is the only practical format for accurately quantifying small molecules (haptens) that cannot be bound by two antibodies simultaneously. Remember that the signal decreases as analyte concentration increases.

2. Innovations and Frontiers in ELISA Technology

Recent ELISA innovations after 2020 have centered on re‑engineering assay architectures, embedding powerful biochemical amplification modules, and migrating from simple colorimetric plate readers to multiplexed optical, electrochemical, and AI‑assisted detection systems.

2.1 ELISA design: architectures, microfluidics, and digital formats

Recent work has shifted ELISA away from static 96‑well plates toward integrated microfluidic and digital‑microfluidic (DMF) formats that automate multistep workflows, minimize sample volume, and support high‑throughput multiplexing ^[4,5].

• Kaixin Su et al.'s review on integrated DMF platforms highlights electrowetting‑on‑dielectric (EWOD) chips that perform all major ELISA steps (dispensing, mixing, incubation, washing, detection) on droplets, achieving higher sensitivity and lower reagent consumption than conventional plates and enabling automated immunoassays for analytes such as IL‑6, IL‑8, and GM‑CSF ^[4].
• The same review describes the integration of DMF with droplet ELISA, in which individual immunocomplexes are compartmentalized into tiny droplets for digital readout, as pioneered by Walt’s group, thereby improving sample use efficiency and supporting single‑molecule or near-single-molecule detection ^[4].
• Microfluidic analyzer platforms such as Huamaxing’s M2a/M5a chemiluminescence immunoassay system, Micropoint’s mLabs fluorescence immunoassay analyzer, and ProteinSimple’s Ella are cited as clinically oriented devices that embed ELISA‑like assays into fully automated microfluidic cartridges, increasing throughput and reproducibility ^[4].

Beyond chip‑scale fluidics, “intelligent” device design is emerging, combining microfluidics with embedded computation and AI‑driven control.

• Kaixin Su et al. DMF review notes that EWOD‑based platforms are being miniaturized and integrated with on‑chip electronics and portable readers, supporting point‑of‑care ELISA‑type assays by reducing footprint, energy consumption, and operator intervention ^[4].

In parallel, there is a sustained effort in surface and capture‑chemistry design within traditional plate formats ^[5].

• Hye-Bin Jeon et al.'s review in Biosensors and Bioelectronics also emphasizes advanced surface engineering (e.g., mixed self‑assembled monolayers, polymer brushes, oriented antibody immobilization) to increase antigen-capture efficiency and reduce nonspecific adsorption, thereby directly improving dynamic range and detection limits in otherwise classical sandwich ELISA configurations ^[5].

2.2 Signal amplification: synthetic biology, nanomaterials, and in situ generation

Modern ELISA development increasingly treats the immunocomplex as a trigger for programmable biochemical amplification rather than a direct link to a single enzyme reaction ^[5,6].

• Hye-Bin Jeon's team summarizes how expression immunoassays, CRISPR‑linked immunoassays (CLISA), and T7 RNA polymerase–linked immunosensing assays couple antigen recognition to transcription or translation cascades, generating large numbers of nucleic acids or proteins from a single binding event and pushing ELISA limits into the low‑femtomolar or attomolar range ^[5].
• They also describe TLISA (T7 RNA polymerase‑linked immunoassay), where a capture–detection antibody pair controls T7 RNAP activity; the polymerase then produces abundant RNA product that is quantified by qPCR or other nucleic‑acid readouts, yielding orders‑of‑magnitude sensitivity gains over conventional HRP/TMB systems ^[5].

Nanomaterial‑based and electrochemiluminescent (ECL) amplification strategies have also advanced rapidly ^[5].

• Electrochemiluminescent ELISA designs incorporating nanomaterials, such as gold nanoclusters paired with MnO2 quenching, have achieved tumor necrosis factor‑α detection limits around 36 fg/mL, roughly two orders of magnitude below conventional assays ^[5].

Another frontier is "in situ amplification" of protein targets themselves rather than solely amplifying reporter signals ^[6].

• A 2025 study in Analytica Chimica Acta reports a strategy in which captured protein biomarkers are enzymatically amplified—effectively generating recombinant copies during the assay—and then detected via a standard ELISA step, enabling femtomolar detection using familiar workflows and instrumentation ^[6].

Synthetic‑biology concepts increasingly intersect with CRISPR‑based detection ^[5,7].

• Reviews of CRISPR diagnostics and the 2025 ELISA‑sensitivity paper both highlight CLISA‑type platforms where antibody–antigen complexes gate CRISPR/Cas nuclease activity, and the ensuing trans‑cleavage of reporter oligonucleotides yields strong fluorescence or electrochemiluminescence, bridging classical ELISA recognition with cutting‑edge nucleic‑acid amplification technologies ^[5,7].

2.3 Detection systems: from colorimetric plates to multiplexed, digital, and AI‑assisted readouts

Detection has evolved from simple absorbance measurements to a diverse landscape of optical, electrochemical, and digital readouts designed for higher sensitivity, multiplexing, and automation ^[4,5].

2.3.1 Optical and chemiluminescent detection

Colorimetric ELISA remains dominant in many settings, but next‑generation platforms are rapidly adopting fluorescence and chemiluminescence to extend dynamic range and lower detection limits.

• Market and technology analyses cited in scientific reviews show that microfluidic ELISA systems using fluorescence or chemiluminescence achieve better performance at small path lengths than colorimetric systems, compensating for the reduced optical path inherent to microchannels.
• In microfluidic chemiluminescence analyzers (e.g., M2a/M5a) documented in the 2024 integrated DMF review, on‑chip photodetectors measure emitted light from small reaction chambers, reducing background signals and enabling rapid, sensitive detection recommended for clinical analytes ^[4].

Time‑domain and dynamic‑range engineering is another active area.

• A 2025 article in Microsystems & Nanoengineering reports an optofluidic time‑domain modulation scheme combined with a high‑dynamic‑range camera for digital ELISA imaging. By temporally modulating illumination and integrating signals, the system simultaneously captures bright saturated and dim signals, enabling accurate counting of both high‑ and low‑abundance targets in a single field ^[8].

2.3.2 Digital and single‑molecule detection

Digital ELISA (dELISA) converts analog enzyme activity into binary events in tiny volumes so that individual molecules can be counted ^[5,9].

• The 2025 ELISA‑sensitivity review describes dELISA and femtoliter chamber arrays as key to achieving single‑molecule detection of proteins and nucleic acids, with analytical sensitivity improvements of up to three orders of magnitude compared with conventional plate ELISA across biomarkers such as IL‑17A and PSA ^[5].
• A 2025 Sensors and Actuators B paper introduces an evaporation‑driven digital ELISA platform based on micro‑droplet arrays. Controlled solvent evaporation concentrates analytes within picoliter‑scale droplets, enhancing signal and allowing accurate quantification in diluted human plasma with over 86% recovery and minimal nonspecific adsorption, without requiring beads or oil phases ^[9].

Digital imaging and analysis are increasingly paired with machine learning.

• The 2024 integrated DMF review notes applications where high‑resolution images of ELISA spots or droplets are processed by custom algorithms for automated spot recognition and intensity quantification, reducing subjective interpretation and enabling rapid, multiplex cytokine profiling ^[4].

2.3.3 Electrochemical and hybrid detection

Electrochemical readouts form a parallel frontier, particularly within microfluidic ELISA ^[5].

• The 2025 ELISA‑sensitivity review highlights electrochemiluminescent and other electrochemical labels as essential for combining very low limits of detection with a wide dynamic range, especially when paired with nanostructured electrodes that increase effective surface area and signal‑to‑noise ratio ^[5].

Hybrid systems also emerge where ELISA‑style capture interfaces with high‑information‑content detectors ^[9].

• A 2023 Nature Communications paper describes a nanopore‑based assay for the detection of multiplexed viral antigen and RNA. Although not a classical plate ELISA, it uses antibody or aptamer capture followed by nanopore sensing to discriminate SARS‑CoV‑2 variants with single‑nucleotide resolution, illustrating how immunoaffinity capture can feed into third‑generation sequencing‑like readouts ^[9].

2.4 Other: Paper‑based, portable, and point‑of‑care ELISA

Paper‑based ELISA (p‑ELISA) chips with multilayer “merry‑go‑round” designs integrate multiple reaction chambers and one‑way flow control into low‑cost substrates, enabling automatic, electricity‑light assays suitable for decentralized testing ^[11].

Market and technology analyses highlight strong investment in portable and point‑of‑care (POC) ELISA devices, driven by infectious and chronic disease diagnostics, with an emphasis on rugged, miniaturized hardware and faster workflows.

• These POC‑oriented platforms often couple microfluidics, dried reagents, and smartphone or compact readers, positioning ELISA as a field‑deployable alternative to centralized lab immunoassays ^[11].

3. Evolving Applications of ELISA: From Lab Bench to Real World

Driven by technological advancements such as plasmonic nanotechnology, microfluidics, CRISPR integration, and AI-assisted detection, modern ELISA is evolving toward higher sensitivity, broader analyte coverage, higher plex and throughput, and tighter integration with computational and microfluidic technologies, while remaining a reference method for quantitative or qualitative protein measurement.

3.1 Clinical diagnostics and serology

ELISA remains central to infectious disease serology and is being systematically evaluated against newer platforms.

• A 2025 Scientific Reports study compared an in‑house SARS‑CoV‑2 IgG ELISA with a commercial Elecsys CLIA and a rapid lateral flow assay, reporting overall agreement of 80.8% with CLIA and showing that the ELISA is a reliable, cost‑effective tool for large‑scale serosurveillance ^[12].
• Another Scientific Reports paper (2022) assessed whether SARS‑CoV‑2 IgG/IgM ELISAs can serve as proxies for plaque‑reduction neutralization tests; IgG and IgM ELISA titers targeting the spike receptor‑binding domain correlated with neutralizing antibody levels, supporting ELISA as a practical surrogate when BSL‑3 neutralization assays are infeasible ^[13].

3.2 Ultrasensitive digital ELISA in virology and neurology

Ultrasensitive digital ELISA has enabled applications that were not possible with traditional assays.

• A 2023 Scientific Reports article showed that digital ELISA (Simoa) for HIV‑1 p24 yields strongly correlated measurements with conventional ELISA yet detects p24 earlier and at lower levels in quantitative viral outgrowth assays, improving measurement of latent HIV reservoirs central to cure research ^[14].
• A 2025 Scientific Reports study compared Simoa digital ELISA, high‑sensitivity ELISA, and chemiluminescent immunoassay for neurofilament light chain, concluding that digital ELISA and high‑sensitivity ELISA both enable NfL quantification in blood, whereas earlier ELISAs were limited to cerebrospinal fluid, broadening NfL’s use as a minimally invasive biomarker of neuroaxonal damage ^[15].

3.3 High‑plex and high‑throughput ELISA‑like platforms

New "next‑generation" ELISA architectures emphasize high plex and throughput while retaining ELISA‑style specificity.

• A 2025 Nature Methods article describes nELISA, a bead‑based platform capable of high‑throughput, high‑plex protein quantification using encoded antibody pairs. The authors report applications in biomarker discovery, immune monitoring, and clinical diagnostics, with performance comparable to or exceeding conventional ELISA in terms of sensitivity and specificity ^[16].
• Another 2025 article on analytical techniques for nucleic acid and protein detection highlights ELISA’s role as a reference method for protein assays. It discusses how signal‑amplified and digital variants have extended their dynamic range and applicability in clinical diagnostics ^[17].

3.4 Food safety and environmental monitoring

Recent work also uses ELISA to address food safety and contaminant monitoring.

• A 2025 Scientific Reports paper presents a nanobody‑based indirect competitive ELISA for aflatoxin M1 in dairy products. The assay achieved sensitive and rapid detection of AFM1 suitable for routine surveillance of milk and related products using a high‑affinity nanobody (Nb M4) ^[18].
• A 2020 Nature Communications article introduced a rapid, highly sensitive biomarker detection platform that mimics ELISA on a microfluidic chip and demonstrated its applicability to hormones and pathogen‑related markers, illustrating how ELISA principles are being translated into faster, chip‑based food and environmental tests ^[19].

3.5 Integration with AI and predictive diagnostics

ELISA is increasingly embedded in broader predictive and AI‑assisted diagnostic frameworks rather than used in isolation.

• A 2024 Nature Communications study on "rapid deep learning‑assisted predictive diagnostics" explicitly notes that standard ELISAs typically require 3–5 hours, and contrasts this with a rapid platform that couples immunoassay‑type measurements to deep learning models for early clinical decision‑making, underscoring the push to augment classical ELISA with computational tools ^[20].